ATE533514T1 - Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern - Google Patents
Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpernInfo
- Publication number
- ATE533514T1 ATE533514T1 AT04806061T AT04806061T ATE533514T1 AT E533514 T1 ATE533514 T1 AT E533514T1 AT 04806061 T AT04806061 T AT 04806061T AT 04806061 T AT04806061 T AT 04806061T AT E533514 T1 ATE533514 T1 AT E533514T1
- Authority
- AT
- Austria
- Prior art keywords
- polyethylene glycol
- antibodies
- branched polyethylene
- polymer residue
- linking polymer
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002062 molecular scaffold Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyethers (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329825.4A GB0329825D0 (en) | 2003-12-23 | 2003-12-23 | Biological products |
| PCT/GB2004/005246 WO2005061005A2 (en) | 2003-12-23 | 2004-12-14 | Branched polyethylene glycol for linking polymer residues to antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533514T1 true ATE533514T1 (de) | 2011-12-15 |
Family
ID=30776372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04806061T ATE533514T1 (de) | 2003-12-23 | 2004-12-14 | Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7736635B2 (de) |
| EP (1) | EP1699491B1 (de) |
| JP (1) | JP4833857B2 (de) |
| AT (1) | ATE533514T1 (de) |
| AU (1) | AU2004305291B2 (de) |
| CA (1) | CA2545805A1 (de) |
| ES (1) | ES2374201T3 (de) |
| GB (1) | GB0329825D0 (de) |
| WO (1) | WO2005061005A2 (de) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| EP1861125A2 (de) * | 2005-03-23 | 2007-12-05 | Nektar Therapeutics Al, Corporation | Konjugate eines hgh-teils und peg-derivate |
| ES2382879T3 (es) | 2005-09-14 | 2012-06-14 | Ucb Pharma, S.A. | Conjugado de anticuerpo - polímero de peine. |
| EP2125894B1 (de) | 2007-03-22 | 2018-12-19 | Biogen MA Inc. | Bindungsproteine mit antikörpern, antikörperderivaten und antikörperfragmenten mit spezifischer bindung an cd154 sowie ihre verwendung |
| AU2008334942A1 (en) * | 2007-12-13 | 2009-06-18 | Aduro Biotech | Ligand conjugated thermotherapy susceptors and methods for preparing same |
| DK2279007T3 (en) * | 2008-04-29 | 2016-08-22 | Ascendis Pharma Growth Disorders Div As | Pegylated recombinant relations of human growth hormone |
| CH700543A2 (de) * | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
| DK2512450T3 (en) | 2009-12-15 | 2018-04-23 | Ascendis Pharma Endocrinology Div A/S | Dry growth hormone composition transiently bound to a polymer carrier |
| US8816099B2 (en) | 2010-03-31 | 2014-08-26 | Nof Corporation | Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof |
| JP5945896B2 (ja) | 2011-09-30 | 2016-07-05 | 日油株式会社 | 分岐型ヘテロ多官能性ポリオキシアルキレン化合物、及びその中間体 |
| CA2872908C (en) | 2012-05-10 | 2023-11-14 | Gerhard Frey | Multi-specific monoclonal antibodies |
| CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| EP3193915A1 (de) | 2014-07-21 | 2017-07-26 | Novartis AG | Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP4205749A1 (de) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimierte chimäre antigenrezeptorhaltige zellen |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| RU2020117196A (ru) | 2014-08-19 | 2020-10-15 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| US10799563B2 (en) | 2014-11-18 | 2020-10-13 | Ascendis Pharma Endocrinology Division | Polymeric hGH prodrugs |
| PL3220892T3 (pl) | 2014-11-21 | 2022-01-31 | Ascendis Pharma Endocrinology Division A/S | Postacie dawkowane długo działającego hormonu wzrostu |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| EP3286211A1 (de) | 2015-04-23 | 2018-02-28 | Novartis AG | Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker |
| JP7573262B2 (ja) * | 2015-07-12 | 2024-10-25 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 細胞結合分子の共役のための架橋連結体 |
| EP3316902A1 (de) | 2015-07-29 | 2018-05-09 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen tim-3 |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| KR20180094977A (ko) | 2015-12-17 | 2018-08-24 | 노파르티스 아게 | c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| EP3851457A1 (de) | 2016-01-21 | 2021-07-21 | Novartis AG | Gegen cll-1 gerichtete multispezifische moleküle |
| WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CN109715808A (zh) | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| EP3464375A2 (de) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen |
| US20190336504A1 (en) | 2016-07-15 | 2019-11-07 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| KR20230100748A (ko) | 2016-07-28 | 2023-07-05 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
| CN110267677A (zh) | 2016-08-01 | 2019-09-20 | 诺华股份有限公司 | 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症 |
| MY200337A (en) | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
| EP3574005B1 (de) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| JP2020105072A (ja) * | 2017-03-24 | 2020-07-09 | 協和キリン株式会社 | ポリエチレングリコール誘導体 |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| US20200223924A1 (en) | 2017-06-27 | 2020-07-16 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| BR112020000719A2 (pt) | 2017-07-11 | 2020-07-14 | Compass Therapeutics Llc | anticorpos agonistas que ligam o cd137 humano e seus usos |
| CN111163798A (zh) | 2017-07-20 | 2020-05-15 | 诺华股份有限公司 | 用于抗lag-3抗体的给药方案及其用途 |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3797120A1 (de) | 2018-05-21 | 2021-03-31 | Compass Therapeutics LLC | Zusammensetzungen und verfahren zur steigerung der abtötung von zielzellen durch nk-zellen |
| WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| EP3801769A1 (de) | 2018-05-25 | 2021-04-14 | Novartis AG | Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car) |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| CA3104295A1 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| BR112021008795A2 (pt) | 2018-11-13 | 2021-08-31 | Compass Therapeutics Llc | Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos |
| MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| CA3123356A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| EP3927744A1 (de) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunktionelle moleküle, die an t-zell-verwandte krebszellen binden, und verwendungen davon |
| WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| SG11202108735QA (en) | 2019-03-04 | 2021-09-29 | Ascendis Pharma Endocrinology Div A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| JP2022527790A (ja) | 2019-03-29 | 2022-06-06 | アターガ，エルエルシー | 抗ｆｇｆ２３抗体分子 |
| AU2020370832A1 (en) | 2019-10-21 | 2022-05-19 | Novartis Ag | TIM-3 inhibitors and uses thereof |
| BR112022007376A2 (pt) | 2019-10-21 | 2022-07-05 | Novartis Ag | Terapias de combinação com venetoclax e inibidores de tim-3 |
| CN114761037A (zh) | 2019-11-26 | 2022-07-15 | 诺华股份有限公司 | 结合bcma和cd19的嵌合抗原受体及其用途 |
| TW202135859A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 組合療法 |
| EP4084823A4 (de) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | Anti-tcr-antikörpermoleküle und ihre verwendungen |
| MX2022008763A (es) | 2020-01-17 | 2022-07-27 | Novartis Ag | Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica. |
| EP4090762A1 (de) | 2020-01-17 | 2022-11-23 | Becton, Dickinson and Company | Methoden und zusammensetzungen für einzelzellsekretomik |
| BR112022016633A2 (pt) | 2020-02-27 | 2022-12-13 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4182025A1 (de) | 2020-07-16 | 2023-05-24 | Novartis AG | Anti-betacellulin-antikörper, fragmente davon und multispezifische bindungsmoleküle |
| WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
| MX2023005609A (es) | 2020-11-13 | 2023-05-29 | Novartis Ag | Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car). |
| JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
| EP4522757A2 (de) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs |
| JP2025528068A (ja) | 2022-08-03 | 2025-08-26 | ボイジャー セラピューティクス インコーポレイテッド | 血液脳関門を通過させるための組成物及び方法 |
| WO2024168061A2 (en) | 2023-02-07 | 2024-08-15 | Ayan Therapeutics Inc. | Antibody molecules binding to sars-cov-2 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026036047A1 (en) | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB315450A (en) | 1928-04-10 | 1929-07-10 | Hozumi Kita | Improvements in door controlling apparatus |
| GB315457A (en) | 1928-04-13 | 1929-07-15 | Reyrolle A & Co Ltd | Improvements in or relating to electric couplings |
| US1890060A (en) | 1928-09-22 | 1932-12-06 | Du Pont | Process of polymerizing vinyl derivatives |
| GB329825A (en) | 1929-05-14 | 1930-05-29 | Edward Victor Hammond | Improvements in jockey pulley apparatus |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP1541682A3 (de) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) * | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69531148T2 (de) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | Bibliotheken aus polyklonalen antikörpern |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US7005504B2 (en) * | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| ATE268609T1 (de) * | 1998-03-12 | 2004-06-15 | Nektar Therapeutics Al Corp | Polyethylenglycolderivate mit benachbarten reaktiven gruppen |
| US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6251382B1 (en) * | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| DE10048417A1 (de) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
| JP4602577B2 (ja) * | 2001-03-15 | 2010-12-22 | 積水メディカル株式会社 | 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬 |
| GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| US20030211078A1 (en) * | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
| ES2291620T3 (es) | 2002-03-13 | 2008-03-01 | Beijing Jiankai Technology Co., Ltd. | Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior. |
| DE60329627D1 (de) * | 2002-12-31 | 2009-11-19 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| KR100512483B1 (ko) * | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| GB0319588D0 (en) | 2003-08-20 | 2003-09-24 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004253738A1 (en) | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
| DE10329948B4 (de) | 2003-07-03 | 2005-05-25 | Koenig & Bauer Ag | Heftapparat mit einem wenigstens zwei Heftköpfe tragenden Heftzylinder |
| AU2003903500A0 (en) | 2003-07-08 | 2003-07-24 | Robinson, Samantha Renae | Display device for greeting cards |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
-
2003
- 2003-12-23 GB GBGB0329825.4A patent/GB0329825D0/en not_active Ceased
-
2004
- 2004-12-14 ES ES04806061T patent/ES2374201T3/es not_active Expired - Lifetime
- 2004-12-14 CA CA002545805A patent/CA2545805A1/en not_active Abandoned
- 2004-12-14 AT AT04806061T patent/ATE533514T1/de active
- 2004-12-14 EP EP04806061A patent/EP1699491B1/de not_active Expired - Lifetime
- 2004-12-14 WO PCT/GB2004/005246 patent/WO2005061005A2/en not_active Ceased
- 2004-12-14 US US10/583,642 patent/US7736635B2/en not_active Expired - Fee Related
- 2004-12-14 AU AU2004305291A patent/AU2004305291B2/en not_active Ceased
- 2004-12-14 JP JP2006546297A patent/JP4833857B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005061005A3 (en) | 2005-11-03 |
| AU2004305291A1 (en) | 2005-07-07 |
| ES2374201T3 (es) | 2012-02-14 |
| EP1699491A2 (de) | 2006-09-13 |
| JP2007515463A (ja) | 2007-06-14 |
| EP1699491B1 (de) | 2011-11-16 |
| GB0329825D0 (en) | 2004-01-28 |
| AU2004305291B2 (en) | 2010-06-24 |
| CA2545805A1 (en) | 2005-07-07 |
| US20070128150A1 (en) | 2007-06-07 |
| WO2005061005A2 (en) | 2005-07-07 |
| US7736635B2 (en) | 2010-06-15 |
| JP4833857B2 (ja) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE533514T1 (de) | Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern | |
| Jad et al. | Green solid-phase peptide synthesis (GSPPS) 3. Green solvents for Fmoc removal in peptide chemistry | |
| CY1108685T1 (el) | Συστημα απελευθερωσης φαρμακου που πηζει in-situ | |
| EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
| NO20072997L (no) | Posisjonsstyrt omdanning av FVIII | |
| CY1118120T1 (el) | Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων | |
| DE60322111D1 (de) | Verfahren zur herstellung von hydrogelen aus thiosulfonat-zusammensetzungen und ihre verwendungen | |
| MX382756B (es) | Polimeros de tiol-eno degradables y metodos para hacer los mismos. | |
| BRPI0607988A2 (pt) | composto, composição farmacêutica, e método para induzir apoptose em uma célula | |
| CY1113684T1 (el) | Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη | |
| WO2004099231A3 (en) | Glycopegylation methods and proteins/peptides produced by the methods | |
| DK1144607T5 (da) | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger | |
| ATE272654T1 (de) | Neue vernetzte derivate der hyaluronsäure. | |
| DK1656410T3 (da) | Fremgangsmåde til fremstillilng af funktionaliserede polymere fra polymeralkoholer | |
| GT200800154A (es) | N-sulfonilacion selectiva de alcoholes 2-amino trifluoroalquilo sustituidos | |
| DE69821376D1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
| WO2004028272A3 (en) | Injectable growth promoting and anthelmintic composition | |
| DK1198570T3 (da) | Monomert protein af TGF-Beta-familien | |
| AR067627A1 (es) | Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion | |
| ATE306498T1 (de) | Von zellen präsentierte peptide | |
| ATE407703T1 (de) | Verbindungen und kits zur herstellung von bildgebenden mitteln und bildgebungsverfahren | |
| ATE498022T1 (de) | Universelle vervielfältigung von fragmentierter rns | |
| ATE253917T1 (de) | Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung | |
| DE602006013151D1 (de) | Verfahren zur herstellung von polymermaleimiden | |
| DE602004021501D1 (de) | Gegenüber ionisierender strahlung stabile polyarylestercarbonatzusammensetzungen |